Insider · CIK 0001359574
Nancy A Simonian
Files at SYRS (Syros Pharmaceuticals, Inc.), GENB (Generate Biomedicines, Inc.). First filing Nov 27, 2024, latest Dec 4, 2024.
In brief
Nancy A Simonian files SEC Form 4 as director at SYRS (Syros Pharmaceuticals, Inc.), and also at GENB (Generate Biomedicines, Inc.). Since Nov 27, 2024, Nancy A Simonian has reported 0 open-market buys worth $0 and 2 open-market sells worth $46k, the latest filed on Dec 4, 2024.
A track record needs three past buys with six months of prices behind them; Nancy A Simonian has 0, so none is measured yet.
The newest scored trade: sold $10k of SYRS on Dec 2, 2024, filed Dec 4, 2024, scored 50 (moderate).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SYRS: Syros Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | Syros Pharmaceuticals, Inc. | $10k 37,070 shares | -90% | - | |
| 56Moderate | Syros Pharmaceuticals, Inc. | $36k 134,713 shares | -77% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 2, 2024 | SYRS SYROS PHARMACEUTICALS, INC. | 37,070 0.14% of outstanding | $10k | Dec 2, 2024 | none |
| Nov 25, 2024 | SYRS Syros Pharmaceuticals, Inc. | 134,713 0.50% of outstanding | $27k | Nov 25, 2024 | none |
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | GENB Generate Biomedicines, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +29,561 | $0.00 | $0 | 29,561 | Mar 2, 2026 |
| Dec 2, 2024 | SYRS Syros Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -37,070 | $0.27 | $10k | 4,000 | Dec 4, 2024 |
| Nov 25, 2024 | SYRS Syros Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -134,713 | $0.27 | $36k | 41,070 | Nov 27, 2024 |
| Oct 31, 2024 | SYRS Syros Pharmaceuticals, Inc. | MOption exercise Common Stock | +40,125 | - | - | 175,783 | Nov 4, 2024 |
| Oct 31, 2024 | SYRS Syros Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -40,125 | $0.00 | $0 | 0 | Nov 4, 2024 |
Questions about Nancy A Simonian
Answered from the filings on this page, as of the latest one.
Is Nancy A Simonian buying or selling?
Not in the last 12 months. Nancy A Simonian's latest open-market trade on SEC Form 4 was sold $10k of SYRS on Dec 2, 2024.
How did Nancy A Simonian's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Nancy A Simonian has 0.
Where does Nancy A Simonian file Form 4?
Nancy A Simonian has filed Form 4 at SYRS (Syros Pharmaceuticals, Inc.); GENB (Generate Biomedicines, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.